Dr. Kambhampati on Updates in Myeloma from the 2018 ASCO Annual Meeting

Video

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

The biggest unmet need in myeloma is how to treat patients who are refractory to lenalidomide (Revlimid), bortezomib (Velcade), or those who have penta-refractory disease. At the 2018 ASCO Annual Meeting, impressive data were presented on the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121. Data showed that patients could achieve progression-free survival (PFS) of approximately 1 year. Additionally, almost all patients who were evaluable for minimal residual disease (MRD) achieved MRD-negativity, which translated into better PFS. These data underscore the importance of CAR T-cell therapy and immunotherapy in myeloma, says Kambhampati.

Additionally, many abstracts centered around dose and schedule alterations of already existing agents. For example, data on carfilzomib (Kyprolis) showed better results by changing the frequency of administration from twice a week to once a week with no added toxicity, states Kambhampati.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD